IM-17(IM-17) - 在研适应症：心肌再灌注损伤_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点-

作用机制

细胞凋亡抑制剂

治疗领域

心血管疾病其他疾病

在研适应症

心肌再灌注损伤

非在研适应症-

原研机构

Riken Corp.

在研机构

Riken Corp.

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 IM-17 相关的临床结果

登录后查看更多信息

100 项与 IM-17 相关的转化医学

登录后查看更多信息

100 项与 IM-17 相关的专利（医药）

登录后查看更多信息

1

项与 IM-17 相关的文献（医药）

2024-09-01·Indian Journal of Microbiology

Characterization of Water-Soluble Extracellular Polysaccharide from Aeribacillus pallidus IM17

Article

作者: Genc, Berna ; Tunç, Merve Tuğçe ; Adiguzel, Ahmet

The production of the extracellular polysaccharide from the thermophilic bacterium Aeribacillus pallidus was carried out in the study. The polysaccharide was isolated and characterized by means of GC-MS, FT-IR, DSC, and XRD analyses. The rheological, foaming, and emulsifying properties of the polysaccharide were determined. Using a sucrose-rich medium, 27.1 mg dried EPS/100 mL was obtained with 94% carbohydrate and 1.5% protein. The monosaccharide profile of water-soluble EPS-IM17 was composed of rhamnose, arabinose, xylose, mannose, glucose, and galactose. The foaming capacity and stability of EPS-IM17 were 26.67% (± 4.71) and 40.01% (± 4.95), respectively, and the foaming stability was not affected by time. The emulsification index of EPS-IM17 was 64.54 (± 8.71) and decreased to 38.47 (± 10.44) after 24 h. EPS-IM17 had a crystalline structure. Solutions at different concentrations (10, 20, 40 mgmL^-1) showed pseudoplastic behavior. In conclusion, this report could be a lead study for the use of Aeribacillus pallidus extracellular polysaccharide for different applications.

100 项与 IM-17 相关的药物交易

登录后查看更多信息